Schering-Plough

Osmind Announces Appointment of Brent Saunders, Pharma Veteran and Former CEO of Allergan, to Board of Directors

Retrieved on: 
Friday, January 21, 2022
Mental Health, Health, Technology, Software, Pharmaceutical, Biotechnology, Coronavirus Scientific Advisory Board (Turkey), Business Roundtable, Patient, Technology, Neuropsychiatry, News, Autism, The Business Council, LinkedIn, Professional corporation, Cisco Systems, AbbVie, Business, CEO, Schering-Plough, Mental health, Brenton L. Saunders, Instagram, EHR, Health, Actavis, Forest Laboratories, Drug development, Director, Therapy, Neurological disorder, Twitter, Bausch Health, Pharmaceutical Research and Manufacturers of America, Policy, Board, Acquisition, Management, Pharmaceutical industry, Allergan, Merck

The news comes on the heels of Osminds recent addition of new members to its senior leadership team and Scientific Advisory Board .

Key Points: 
  • The news comes on the heels of Osminds recent addition of new members to its senior leadership team and Scientific Advisory Board .
  • Mr. Saunders brings to Osmind over 25 years of expertise in the pharmaceutical and life sciences industries.
  • Next, he became CEO and President of Forest Laboratories, and following its merger with Actavis, became CEO of the combined business as well.
  • As CEO, he led Actavis acquisition of Allergan and became CEO of the combined entity, which was renamed Allergan Plc.

PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications

Retrieved on: 
Wednesday, January 19, 2022
Stomach, PLX, Bachelor of Arts (film), MBA, NASDAQ, Reckitt, Wellness, CEO, Dickinson College, Absorption, GLOBE, Merck, Bed Bath & Beyond, Corporate communication, Aspirin, API, OBI Pharma, Inc., OTC, Pain, Company, Bed, Schering-Plough, Risk, Patent, FDA, Seton Hall University, Senior, Degenerative disease, Pharmaceutical industry, Management

The Company, with its lead products VAZALORE 325 mg and VAZALORE 81 mg liquid-filled aspirin capsules (referred to together as VAZALORE), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately.

Key Points: 
  • The Company, with its lead products VAZALORE 325 mg and VAZALORE 81 mg liquid-filled aspirin capsules (referred to together as VAZALORE), announced today the appointment of Janet M. Barth as Vice President, Investor Relations & Corporate Communications, effective immediately.
  • As a member of the Executive Leadership Team, Ms. Barth will report directly to Natasha Giordano, PLx Pharmas President & CEO.
  • Ms. Barths experience spans nearly 30 years of broad-reaching, finance-driven investor relations and corporate communications with publicly held pharmaceutical and retail companies.
  • Vice President, Investor Relations & Corporate Communications, PLx Pharma Inc.

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

Retrieved on: 
Tuesday, January 18, 2022
NTM, Patient, Man, LinkedIn, Joseph M. Katz Graduate School of Business, Inflammation, University, Degenerative disease, General officer, Testosterone, MAC, University of Pittsburgh, Medical Affairs Bureau, Schering-Plough, Solution, GLOBE, Immunology, Leadership, ALIS, History, Industry, AstraZeneca, Therapy, Urology, Drug development, Complex, Joseph, Twitter, Amikacin, Mycobacterium avium complex, Woman, Pharmaceutical industry, Insming, Pfizer, Merck, Zeneca

NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022. Dr. Jumadilova has nearly 30 years of experience in the pharmaceutical and biotech industries. She most recently led clinical development programs at Insmed and Pfizer.

Key Points: 
  • NORTHBROOK, Ill., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Clarus Therapeutics Holdings, Inc. (Clarus) (Nasdaq:CRXT), a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women, today announced the appointment of Zhanna Jumadilova, M.D., M.B.A., as Chief Clinical Development Officer, effective January 17, 2022.
  • She most recently led clinical development programs at Insmed and Pfizer.
  • Zhanna joins Clarus at a transformative time in our history as we further the clinical development of our pipeline assets, said Dr. Robert Dudley, President and Chief Executive Officer of Clarus.
  • With her proven leadership and extensive expertise in drug development, along with her ability to navigateglobal regulatory environments, Zhanna will be a tremendous asset as we progress Clarus pipeline.

Alliance Advisors Further Expands Proxy Solicitation Team with Appointment of New Senior Vice President and Banking Expert

Retrieved on: 
Wednesday, January 19, 2022
Professional Services, Other Professional Services, Human Resources, Finance, Consulting, Banking, Harbinger Capital, Bank One Corporation, Trust, Aguinda v. Texaco, Inc., M&A, Community Bank, J. P. Morgan, Bank, Investment, Merrill (company), Mineola, JPMorgan Chase, Insurance, ValueAct Capital, Industry, SSB, LLC, Schering-Plough, Senior, Alliance, Merck, Bank holding company, Oracle

Alliance Advisors, leading global corporate advisory and proxy solicitation firm, is pleased to announce that banking specialist Thomas Cronin has joined Alliance as a Senior Vice President in our Proxy Solicitation Division.

Key Points: 
  • Alliance Advisors, leading global corporate advisory and proxy solicitation firm, is pleased to announce that banking specialist Thomas Cronin has joined Alliance as a Senior Vice President in our Proxy Solicitation Division.
  • Tom is a successful industry veteran with extensive banking experience, making him a key strategic addition to the Alliance organization.
  • Over his career, Tom has worked on over three-hundred friendly M&A transactions, Proxy Contests, bank, thrift, and insurance conversions.
  • Alliance Advisors is a corporate advisory and proxy solicitation firm, specializing in investor intelligence, corporate governance consulting, proxy contests, and proxy logistics management.

Merck Animal Health's Third Veterinarian Wellbeing Study Reveals Increased Health Challenges and Psychological Distress Among Veterinarians

Retrieved on: 
Tuesday, January 18, 2022
MSD, Research, DVM, LinkedIn, SEC, Science, NYSE, U.S. Securities and Exchange Commission, MRK, Animal, Industry, Employee assistance program, Merck & Co., Environment, Prevalence, Awareness, CQD, Technology, Diversity, AVMA, Hobby, American Veterinary Medical Association, COVID-19, Schering-Plough, Suicide, Instagram, Doctor of Philosophy, Human, Family, Workplace, Partnership, Fragile Families and Child Wellbeing Study, Annual report, News, Love, Vaccine, Mental health, Solution, Farmer, Health, Time, Fatigue, Program, Private Securities Litigation Reform Act, Veterinary medicine, Friends, Coronavirus, Risk, Patent, Twitter, Security (finance), Life, Physician, Pharmaceutical industry, Medicine, Merck, Facebook, Veterinarian

And at Merck Animal Health, we have unconditional respect for veterinary professionals and their dedicated service, particularly during these unconventional times," said Christine Royal, DVM, associate vice president, U.S. Companion Animal and Equine, Merck Animal Health.

Key Points: 
  • And at Merck Animal Health, we have unconditional respect for veterinary professionals and their dedicated service, particularly during these unconventional times," said Christine Royal, DVM, associate vice president, U.S. Companion Animal and Equine, Merck Animal Health.
  • AVMA and Merck Animal Health are devoted to providing techniques and solutions that improve veterinary mental health and wellbeing, now and for future generations.
  • Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.
  • Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them.

Cybersecurity: The 5 Things Leaders Need to Know

Retrieved on: 
Saturday, January 15, 2022
Corporate title, Technology, The Vanguard Group, HBR, CEO, Schering-Plough, Vanguard, Leadership, AI, Chief executive officer, GC, Medical device, Management, Tenneco, United Airlines, Walgreens

Most who get attacked wish dearly they had thought it through in advance.

Key Points: 
  • Most who get attacked wish dearly they had thought it through in advance.
  • On January 20, 2022, http://www.thevanguardnetwork.com will present an in-depth online dialogue with a panel of cybersecurity and AI experts to discuss what senior executives really need to know.
  • It is aimed at C-Suite leaders, who can ask questions, discuss, and share successes and cautionary tales.
  • The dialogue is one of an array of membership benefits of the Vanguard Network, which organizes events, publishes content and connects C-suite leaders.

Vaxxinity Appoints Jason Pesile as SVP, Finance & Accounting, and George Hornig to Board of Directors

Retrieved on: 
Tuesday, January 4, 2022
Slate, COVID-19, Private Securities Litigation Reform Act, Housing, Communities and Local Government Committee, U.S. Securities and Exchange Commission, Board, Secretary of State of New Jersey, Wasserstein Perella & Co., Wendell Pritchett, Columbia Business School, Forrester Research, Risk, Skadden, Company, Harvard University, Merchant, Hypercholesterolemia, Migraine, Schering-Plough, Merck, COO, Professional Football Compensation Committee, Audit, MBA, Wharton School of the University of Pennsylvania, GLOBE, Market for corporate control, Financial compensation, Vaccine, University, Accounting, Security (finance), Technology, Conditional sentence, CPA, Pinebridge Bucks, Audit committee, Health, First Boston, Century, Senior, Board of directors, Nasdaq, Efficiency, Acquisition, Partner (business rank), Pakistan Institute of Public Finance Accountants, Management, Xometry

The Company also announced today the appointment of George Hornig, Chairman of Xometry, to its Board of Directors.

Key Points: 
  • The Company also announced today the appointment of George Hornig, Chairman of Xometry, to its Board of Directors.
  • We are thrilled to welcome Jason to our management team and George to the Vaxxinity Board, said Mei Mei Hu, Chief Executive Officer of Vaxxinity.
  • The addition of George to our Board of Directors further strengthens our leadership team by bringing nearly 40 years of senior executive-level experience at large, global financial institutions to Vaxxinity.
  • Prior to joining PineBridge, Mr. Hornig spent 11 years at Credit Suisse Asset Management as Managing Director and Global COO.

Legend Biotech Announces Appointment of Dr. Ying Huang to the Board of Directors

Retrieved on: 
Thursday, December 30, 2021
Biotechnology, Pharmaceutical, Health, Oncology, Amgen, Chemistry, Department, European Medicines Agency, BofA Securities, Technology, Board, Special Class Railway Apprentice, Drug discovery, Eric Gleacher, Wall Street, Central nervous system, Chemical substance, NASDAQ, Regulation of tobacco by the U.S. Food and Drug Administration, University of Science and Technology of China, Food, Credit Suisse, Columbia University, BCMA, Research, Knowledge, Biogen, Wells Fargo, Merck & Co., University, Therapy, Board of directors, Patient, Special Class for the Gifted Young, Columbia Business School, RRMM, Biotechnology, Schering-Plough, Merck, Barclays, NK, Multiple myeloma, Chemistry (relationship), Management, Pharmaceutical industry, Wachovia

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotechs Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotechs Board of Directors.

Key Points: 
  • Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today that Dr. Ying Huang, Legend Biotechs Chief Executive Officer and Chief Financial Officer, has been appointed as a director to Legend Biotechs Board of Directors.
  • We are delighted to have Dr. Huang join our Board of Directors, said Sally Wang, Chairwoman of Legend Biotech.
  • As Legend Biotechs Chief Executive Officer and Chief Financial Officer, Dr. Huang has been instrumental to Legend Biotechs progress to date, and his extensive knowledge of Legend Biotech will surely enhance our Board of Directors.
  • Ying Huang, Ph.D., has served as Legend Biotechs Chief Executive Officer since September 2020 and as its Chief Financial Officer since July 2019.

Cronus Pharma Hires Todd Brodersen as Senior Director of Sales & Marketing

Retrieved on: 
Wednesday, December 22, 2021
Biotechnology, Pharmaceutical, Health, Veterinary, Marketing, Knowledge, DISC assessment, Boehringer Ingelheim, Food, Acosta Sales & Marketing, Practice management, Growth, Founder, Health, PAR, Veterinarian, Cephalosporin, Schering-Plough, PVP, Research, Vets Beyond Borders, Fine chemical, Pharmaceutical industry, Cronus

Cronus Pharma LLC, a fully integrated research & development, manufacturing and marketing animal health pharmaceutical company, announced Mr. Todd Brodersen has joined as Senior Director of Sales & Marketing.

Key Points: 
  • Cronus Pharma LLC, a fully integrated research & development, manufacturing and marketing animal health pharmaceutical company, announced Mr. Todd Brodersen has joined as Senior Director of Sales & Marketing.
  • He has extensive knowledge of the animal health market including, sales, marketing, data analytics, distribution channels, market penetration strategies, and practice management.
  • He added, Todd is a proven venerable sales and marketing executive with decades of experience where he formed extensive relationships with customers across the animal health industry.
  • Mr. Brodersen is a certified sales trainer in PAR and DiSC and has trained many sales teams and executives within the animal health industry over the past thirty years.

Covetrus Announces New Structure, Focus and Strength within Europe

Retrieved on: 
Tuesday, December 21, 2021
Biotechnology, Pharmaceutical, Health, Veterinary, MSD, Schering-Plough, Leadership, Health, Face, Technology, Animal, CEO, Security (finance), U.S. Securities and Exchange Commission, VP, Veterinary medicine, Nasdaq, Securities Act of 1933, Solution, GTS, Germany, International, Pfizer, Employment, DACH, Securities Exchange Act of 1934, Management, Central Europe

Earlier this year, Covetrus announced the hiring of Andrs Bolcskei as Covetrus first president of International.

Key Points: 
  • Earlier this year, Covetrus announced the hiring of Andrs Bolcskei as Covetrus first president of International.
  • The U.K. business will increase service to U.K.-based customers through an extended focus of the companys One Face to Customer approach.
  • These moves position Covetrus to win for our European customers and win for our global business, said Ben Wolin, President & CEO.
  • Covetrus is a global animal-health technology and services company dedicated to empowering veterinary practice partners to drive improved health and financial outcomes.